Roger J Porter MD LLC

(#3-CV,p11,#72)

admin — Mon, 08 Sep 2014 06:26:53 +0000

(#3-CV,p11,#72) Porter RJ, Burdette DE, Gil-Nagel A, Hall ST, White R, Shaikh S, DeRossett SE. Retigabine as adjunctive therapy in adults with partial-onset seizures: Integrated analysis of three pivotal controlled trials. Epilepsy Research 101:103-112, 2012.

An integrated analysis of the three pivotal studies leading to the approval of retigabine.

(#3-CV,p11,#75)

admin — Mon, 08 Sep 2014 06:26:14 +0000

(#3-CV,p11,#75) Sachdeo R, Partiot A, Biton V, Rosenfeld WE, Nohria V, Tompson D, DeRossett S, and PorterRJ. A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development. International Journal of Clinical Pharmacology and Therapeutics 52:509-518, 2014.

A unique study which approaches the difficult area of Phase IIA clinical studies of anti-seizure drugs.

(#3-CV,p19,#135)

admin — Mon, 08 Sep 2014 06:25:45 +0000

(#3-CV,p19,#135) Porter RJ, Dhir A, Rogawski M, Macdonald R. AED mechanisms and principles of drug treatment. In Stefan H, and Theodore W (Ed): Handbook of Clinical Neurology, 3^rd series, Epilepsies Part 2: Treatment. Elsevier, Edinburgh, 2012, 663-681.

A definitive, recent review of basic and clinical aspects of anti-seizure drugs.

(#3-CV,p20,#139)

admin — Mon, 08 Sep 2014 06:24:44 +0000

(#3-CV,p20,#139) Porter RJ & Rogawski MA: Antiseizure Drugs. In Katzung BG (Ed): Basic and Clinical Pharmacology, 14^th Edition. Lange/McGraw-Hill, New York, 2018, 409-439.

This definitive chapter, with RJP as senior author for >30 years, has been written and updated biennially since 1982.